Relay Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-276.5M | $-337.7M | $-342.0M | $-290.5M | $-363.9M | $-52.4M | $-75.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $3.6M | $5.5M | $5.3M | $4.1M | $3.9M | $3.5M | $2.8M |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $62.4M | $94.1M | $86.0M | $56.1M | $48.5M | $32.0M | $4.5M |
| Net Cash from Operating Activities | $-235.5M | $-249.1M | $-300.3M | $-229.5M | $-74.4M | $-102.5M | $-66.1M |
| Investing Activities | |||||||
| Capital Expenditures | $410.0K | $2.0M | $4.1M | $9.1M | $3.5M | $1.9M | $8.0M |
| Business Acquisitions | — | — | — | — | $25.3M | — | — |
| Net Cash from Investing Activities | $192.8M | $-41.1M | $257.6M | $-188.7M | $-479.5M | $81.7M | $-319.0M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.6M | $270.2M | $34.8M | $289.9M | $388.1M | $426.5M | $5.6M |
| Net Change in Cash | $-41.1M | $-20.0M | $-7.9M | $-128.3M | $-165.8M | $405.7M | $-379.6M |
| Free Cash Flow | $-235.9M | $-251.1M | $-304.4M | $-238.6M | $-77.9M | $-104.4M | $-74.1M |